Market Overview

22nd Century Receives Order for 3.6 Million SPECTRUM® U.S. Government Research Cigarettes


Very Low Nicotine Content will eliminate all cigarettes' ability
to create and sustain addiction

22nd Century Group, Inc. (NYSE American: XXII),
a plant biotechnology company focused on tobacco harm reduction and Very
Low Nicotine tobacco, announced today that the National Institute on
Drug Abuse (NIDA), the U.S. Food and Drug Administration (FDA), and
public health researchers have requested a new, significant quantity of
22nd Century's proprietary SPECTRUM® research cigarettes. In
coordination with NIDA, FDA, and others, RTI International has submitted
an order to 22nd Century for 3.6 million SPECTRUM® research cigarettes.

RTI's newest SPECTRUM® order comes on the heels of the close of the
FDA's public comment period for the FDA's Advanced Notice of Proposed
Rulemaking (ANPRM) to establish a rule that will require that all
cigarettes sold in the United States contain only minimally or
non-addictive levels of nicotine. While the FDA is pressing ahead with
its rule-making process, 22nd Century is simultaneously advancing its
historic Modified Risk Tobacco Product (MRTP) application for the
Company's proprietary "BRAND A" Very Low Nicotine Content (VLNC)
cigarettes. 22nd Century will file its MRTP application before the end
of this year.

Progress on the FDA's planned reduced nicotine mandate mirrors the work
22nd Century has undertaken to create a Very Low Nicotine Cigarette
product standard that will forever change the U.S. tobacco industry.
Very Low Nicotine Content will eliminate all cigarettes' ability to
create and sustain addiction.

With 95% less nicotine than the tobacco contained in the conventional
cigarettes sold by Altria (MO),
Reynolds American, a subsidiary of British American Tobacco (BATS.L),
and the other "Big Tobacco" companies, 22nd Century's VLNC cigarettes
may become the first combustible cigarettes authorized by the FDA as
Modified Risk Tobacco Products.

Independent scientists are currently leading more than two dozen active
clinical studies using 22nd Century's proprietary SPECTRUM® research
cigarettes. Following the completion of numerous clinical studies that
have examined the broad application of VLNC cigarettes to smokers (Donny,
et al
., Hatsukami,
et al
., Mercincavage,
et al
.), researchers are investigating the application and
effect of VLNC cigarettes on more narrow, vulnerable groups in society,
including adolescents, those diagnosed with ADHD, patients with mood and
anxiety disorders, smokers with schizophrenia, and others. The data
collected from these independent studies will add to the deep body of
knowledge gained from already completed clinical studies on the impact
of VLNC cigarettes on public health.

"22nd Century's proprietary SPECTRUM® research cigarettes have been, and
continue to be, the linchpin of the scientific support for both the
FDA's efforts to dramatically reduce nicotine in cigarettes and for 22nd
Century's own MRTP application for VLNC cigarettes," explained Henry
Sicignano III, President and Chief Executive Officer of 22nd Century
Group. "VLN™ SPECTRUM® cigarettes are now widely recognized by public
health advocates as the archetype of all cigarettes to
come… And 22nd Century's offer to license our proprietary tobacco
technology to all interested companies means VLN™ cigarettes may soon be
available – worldwide – to smokers who wish to sever their addiction to


22nd Century developed SPECTRUM® in partnership with independent
researchers and officials from the National Institute on Drug Abuse
(NIDA), the U.S. Food and Drug Administration (FDA), the National Cancer
Institute (NCI), and the Centers for Disease Control and Prevention
(CDC). The main SPECTRUM® product line, uniquely produced by 22nd
Century, consists of a series of cigarette styles that vary nicotine
yields over a 50-fold range – from very low (97% less nicotine than
tobacco contained in conventional cigarette brands) to relatively high
nicotine yields. SPECTRUM® features 24 styles, in both regular and
menthol versions, with 8 different levels of nicotine.

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on technology
which allows it to increase or decrease the level of nicotine in tobacco
plants and the level of cannabinoids in hemp/cannabis plants through
genetic engineering and plant breeding. The Company's primary mission in
tobacco is to reduce the harm caused by smoking. The Company's primary
mission in hemp/cannabis is to develop proprietary hemp strains for
important new medicines and agricultural crops. Visit
for more information.

Cautionary Note Regarding Forward-Looking Statements: This
press release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc., its
directors or its officers with respect to the contents of this press
release, including but not limited to our future revenue expectations.
The words "may," "would," "will," "expect," "estimate," "anticipate,"
"believe," "intend" and similar expressions and variations thereof are
intended to identify forward-looking statements. We cannot guarantee
future results, levels of activity or performance. You should not place
undue reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should be
considered with any written or oral forward-looking statements that we
may issue in the future. Except as required by applicable law, including
the securities laws of the United States, we do not intend to update any
of the forward-looking statements to conform these statements to reflect
actual results, later events or circumstances, or to reflect the
occurrence of unanticipated events. You should carefully review and
consider the various disclosures made by us in our annual report on Form
10-K for the fiscal year ended December 31, 2017, filed on March 7,
2018, including the section entitled "Risk Factors," and our other
reports filed with the U.S. Securities and Exchange Commission which
attempt to advise interested parties of the risks and factors that may
affect our business, financial condition, results of operation and cash
flows. If one or more of these risks or uncertainties materialize, or if
the underlying assumptions prove incorrect, our actual results may vary
materially from those expected or projected.

View Comments and Join the Discussion!